Evaluating Cinnamon Effects on Clinical, Serologic and Sonographic Characteristics of Non-Alcoholic Fatty Liver Disease patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062922977N1

Enrollment

120

Registered

2015-07-20

Start date

2015-07-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: In the treatment group (Cinnamon group) all patients will receive 750 mg cinnamon capsules twice daily for 12 weeks starting after initial assessments. Intervention 2: In the control

Treatment - Drugs

In the treatment group (Cinnamon group) all patients will receive 750 mg cinnamon capsules twice daily for 12 weeks starting after initial assessments

In the control group, all patients will receive 750 mg placebo capsules (wheat flour) of identical shape and color twice daily for 12 weeks starting after initial assessments

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (consenting NAFLD patients 18-65 years old; evidence of fatty liver in ultrasonography with a score of 2 or more or alanine aminotransferase (ALT) levels up to 60 U/L;) and exclusion criteria (daily alcohol consumption above 20 g in women and 30 g in men; incidence of other acute or chronic liver diseases (hepatitis B, C, etc); cirrhosis; biliary disease; known autoimmune disease; malignancy and/or inherited disorders that affect liver status (an iron storage disease, Wilson disease, etc); pregnancy and lactation; metformin consumption; incidence of hyperlipidemia or hypertension requiring medication; previous supplementation of vitamin E; usage of hepatotoxic drugs over the past 6 months prior to the trial; developing hypersensitivity to cinnamon or occurring any adverse effects; acquiring viral/autoimmune/metabolic hepatic disorders during the study; alcohol intake; withdrawing treatment or being lost to follow up clinical and para-clinical examinations)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fatty liver score in ultrasound. Timepoint: Before intervention and after three months of intervention. Method of measurement: Ultrasound evaluations of abdomen.;Fasting Blood Sugar (FBS). Timepoint: Before intervention and after three months of intervention. Method of measurement: colorimetric enzymatic method.;HbA1C. Timepoint: Before intervention and after three months of intervention. Method of measurement: measured by affinity chromatographic method.;Triglycerides, Total Cholesterol, Low-density Lipoprotein (LDL), and High-density Lipoprotein (HDL). Timepoint: Before intervention and after three months of intervention. Method of measurement: Colorimetric Enzymatic Method.;Serum ALT and AST Concentration. Timepoint: Before intervention and after three months of intervention. Method of measurement: UV Test.;Weight (kg). Timepoint: Before intervention and after three months of intervention. Method of measurement: Digital scale with minimal clothing and no shoes.;Body Mass Index (BMI). Timepoint: Before intervention and after three months of intervention. Method of measurement: Weight (kilograms) divided by the square of height (meters).;Waist Circumference. Timepoint: Before intervention and after three months of intervention. Method of measurement: non-stretchable tape without any pressure (cm).	—

Measure

Time frame

Fatty liver score in ultrasound. Timepoint: Before intervention and after three months of intervention. Method of measurement: Ultrasound evaluations of abdomen.;Fasting Blood Sugar (FBS). Timepoint: Before intervention and after three months of intervention. Method of measurement: colorimetric enzymatic method.;HbA1C. Timepoint: Before intervention and after three months of intervention. Method of measurement: measured by affinity chromatographic method.;Triglycerides, Total Cholesterol, Low-density Lipoprotein (LDL), and High-density Lipoprotein (HDL). Timepoint: Before intervention and after three months of intervention. Method of measurement: Colorimetric Enzymatic Method.;Serum ALT and AST Concentration. Timepoint: Before intervention and after three months of intervention. Method of measurement: UV Test.;Weight (kg). Timepoint: Before intervention and after three months of intervention. Method of measurement: Digital scale with minimal clothing and no shoes.;Body Mass Index (BMI). Timepoint: Before intervention and after three months of intervention. Method of measurement: Weight (kilograms) divided by the square of height (meters).;Waist Circumference. Timepoint: Before intervention and after three months of intervention. Method of measurement: non-stretchable tape without any pressure (cm).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEskandar Hajiani

Ahvaz Jundishapur University of Medical Sciences

hajiani-e@ajums.ac.ir+98 61 1292 1839

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026